Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Immutep Ltd ( (AU:IMM) ) has issued an update.
Immutep Limited has received a €2,588,954 (~ A$4,567,769) R&D tax incentive payment from the French Government under the Crédit d’Impôt Recherche scheme. This funding will support the global clinical development of eftilagimod alfa and IMP761, enhancing Immutep’s operations and potentially strengthening its position in the biotechnology industry.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep is a late-stage biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases. The company is a leader in the advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), with a diversified product portfolio that leverages LAG-3’s ability to modulate the immune response. Immutep is committed to providing innovative treatment options and maximizing shareholder value.
YTD Price Performance: -23.29%
Average Trading Volume: 2,490,040
Technical Sentiment Signal: Hold
Current Market Cap: A$412.1M
Learn more about IMM stock on TipRanks’ Stock Analysis page.